VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.5	267	516	370	3.26e-34	131
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.7	263	516	392	3.52e-34	132
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.1	296	516	365	2.74e-33	129
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.4	309	516	381	4.99e-33	128
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.4	309	516	381	4.99e-33	128
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.8	257	516	354	5.27e-32	125
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.5	233	516	367	1.25e-31	124
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.5	233	516	368	1.27e-31	124
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.7	249	516	352	1.79e-31	123
VatanenT_2016_SRR4408251_bin.5_k119_1215_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	281	516	381	2.97e-31	123
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.7	234	233	229	5.13e-56	177
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.5	228	233	231	3.09e-55	175
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.2	228	233	232	3.18e-55	175
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.6	228	233	219	9.82e-54	171
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.0	231	233	233	1.05e-53	171
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.7	231	233	232	8.18e-53	169
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.7	231	233	232	1.16e-52	169
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.7	231	233	232	1.16e-52	169
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	234	233	231	3.18e-52	167
VatanenT_2016_SRR4408251_bin.5_k119_1215_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.4	230	233	232	6.54e-52	167
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|803568669|ref|WP_046077412.1|	27.6	232	266	648	8.87e-18	81.6
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|446110352|ref|WP_000188207.1|	27.6	232	266	648	8.87e-18	81.6
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|YP_002382193	27.6	232	266	648	8.87e-18	81.6
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|803575554|ref|WP_046081557.1|	27.6	232	266	648	8.87e-18	81.6
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|446110351|ref|WP_000188206.1|	27.6	232	266	648	8.87e-18	81.6
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|502669352|ref|WP_012905216.1|	26.7	232	266	648	7.27e-17	79.0
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|1035670474|ref|WP_064517458.1|	26.3	232	266	648	8.75e-15	72.8
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|1035717981|ref|WP_064557480.1|	26.3	232	266	648	8.75e-15	72.8
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|736472622|ref|WP_034494292.1|	26.3	232	266	648	1.59e-14	72.0
VatanenT_2016_SRR4408251_bin.5_k119_1215_5	SARG|gi|1035706844|ref|WP_064548272.1|	25.9	232	266	648	5.24e-14	70.5
VatanenT_2016_SRR4408251_bin.5_k119_1215_9	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	47.2	159	160	159	1.91e-44	142
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.7	246	247	255	1.98e-29	110
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|803568669|ref|WP_046077412.1|	29.7	202	247	648	5.55e-21	90.5
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|446110352|ref|WP_000188207.1|	29.7	202	247	648	5.55e-21	90.5
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|YP_002382193	29.7	202	247	648	5.55e-21	90.5
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|803575554|ref|WP_046081557.1|	29.7	202	247	648	5.55e-21	90.5
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|446110351|ref|WP_000188206.1|	29.7	202	247	648	5.55e-21	90.5
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|740856590|ref|WP_038641842.1|	27.9	201	247	648	1.38e-20	89.4
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|922960663|ref|WP_053388845.1|	27.9	201	247	648	1.38e-20	89.4
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|757799695|ref|WP_043016897.1|	27.9	201	247	648	1.87e-20	89.0
VatanenT_2016_SRR4408251_bin.5_k119_2014_15	SARG|gi|1045891604|ref|WP_065554100.1|	27.9	201	247	648	1.87e-20	89.0
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|gi|447195835|ref|WP_001273091.1|	35.2	247	309	306	1.78e-38	137
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|gi|447195836|ref|WP_001273092.1|	34.8	247	309	306	4.89e-38	135
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|P42332	29.7	310	309	306	6.84e-38	135
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|ABB80128	29.7	310	309	306	9.58e-38	135
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|ZP_04081918	36.0	214	309	306	1.34e-37	134
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.4	310	309	306	1.88e-37	134
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|gi|510143239|gb|AGN36970.1|	29.4	310	309	313	2.19e-37	134
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	38.6	202	309	293	1.05e-36	132
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|gi|542061059|gb|ERI11611.1|	33.6	226	309	316	2.45e-36	131
VatanenT_2016_SRR4408251_bin.5_k119_2685_37	SARG|gi|445996719|ref|WP_000074574.1|	29.1	309	309	309	4.12e-36	130
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|445996708|ref|WP_000074563.1|	28.7	223	502	309	1.43e-13	70.5
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|507055561|ref|WP_016126482.1|	28.6	217	502	309	1.43e-13	70.5
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|488053456|ref|WP_002124853.1|	29.0	217	502	309	1.43e-13	70.5
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|488067981|ref|WP_002139378.1|	29.0	217	502	309	1.92e-13	70.1
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|507023808|ref|WP_016095885.1|	29.0	217	502	309	1.92e-13	70.1
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|487936534|ref|WP_002010000.1|	29.0	217	502	309	1.92e-13	70.1
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|447057510|ref|WP_001134766.1|	29.0	217	502	309	1.92e-13	70.1
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|488130770|ref|WP_002201978.1|	29.0	217	502	309	2.57e-13	69.7
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|488042066|ref|WP_002113463.1|	29.0	217	502	309	2.57e-13	69.7
VatanenT_2016_SRR4408251_bin.5_k119_2685_53	SARG|gi|447057509|ref|WP_001134765.1|	29.0	217	502	309	2.57e-13	69.7
VatanenT_2016_SRR4408251_bin.5_k119_3608_6	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.0	676	656	703	1.31e-164	487
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|736472622|ref|WP_034494292.1|	37.1	224	287	648	4.98e-40	146
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|502669352|ref|WP_012905216.1|	37.1	224	287	648	6.85e-40	145
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|1035717981|ref|WP_064557480.1|	36.2	224	287	648	2.44e-39	144
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|1035706844|ref|WP_064548272.1|	36.6	227	287	648	6.32e-39	143
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|803568669|ref|WP_046077412.1|	36.6	224	287	648	8.67e-39	142
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|446110352|ref|WP_000188207.1|	36.6	224	287	648	8.67e-39	142
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|YP_002382193	36.6	224	287	648	8.67e-39	142
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|803575554|ref|WP_046081557.1|	36.6	224	287	648	8.67e-39	142
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|446110351|ref|WP_000188206.1|	36.6	224	287	648	8.67e-39	142
VatanenT_2016_SRR4408251_bin.5_k119_3608_8	SARG|gi|1035670474|ref|WP_064517458.1|	36.2	221	287	648	1.19e-38	142
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	31.2	250	818	365	8.00e-27	112
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	32.3	235	818	370	8.67e-27	112
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	29.6	311	818	384	4.77e-26	110
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	29.6	311	818	384	4.77e-26	110
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.6	311	818	386	8.89e-26	109
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	29.6	311	818	386	8.89e-26	109
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.4	289	818	392	1.75e-25	108
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	32.7	220	818	357	3.41e-25	107
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	32.7	220	818	357	3.41e-25	107
VatanenT_2016_SRR4408251_bin.5_k119_3608_34	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	29.9	311	818	386	5.27e-25	107
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	47.8	232	231	233	4.78e-70	213
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.6	228	231	231	1.28e-69	212
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.6	228	231	231	1.28e-69	212
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.1	229	231	232	1.07e-68	209
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.1	229	231	232	1.07e-68	209
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.0	230	231	231	2.73e-66	203
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.6	230	231	231	1.10e-65	202
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.2	230	231	231	1.55e-65	201
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.7	234	231	235	7.09e-65	200
VatanenT_2016_SRR4408251_bin.5_k119_3608_35	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	42.2	230	231	229	1.67e-64	199
VatanenT_2016_SRR4408251_bin.5_k119_3608_47	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	40.3	62	302	346	3.64e-11	62.0
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	512	536	655	1.90e-76	253
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.4	512	536	655	2.66e-76	252
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	2.66e-76	252
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	SARG|gb|AKA86814|ARO:3003746|optrA	31.3	512	536	655	2.66e-76	252
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	7.23e-76	251
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	7.23e-76	251
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	7.23e-76	251
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	7.23e-76	251
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	1.01e-75	251
VatanenT_2016_SRR4408251_bin.5_k119_3732_11	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	512	536	655	1.01e-75	251
VatanenT_2016_SRR4408251_bin.5_k119_3732_27	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	26.8	671	674	633	7.03e-56	200
VatanenT_2016_SRR4408251_bin.5_k119_5402_4	SARG|gi|736472622|ref|WP_034494292.1|	36.8	201	241	648	2.65e-34	128
VatanenT_2016_SRR4408251_bin.5_k119_5402_4	SARG|gi|1035670474|ref|WP_064517458.1|	34.9	232	241	648	3.63e-34	128
VatanenT_2016_SRR4408251_bin.5_k119_5402_4	SARG|gi|1035717981|ref|WP_064557480.1|	34.9	232	241	648	3.63e-34	128
VatanenT_2016_SRR4408251_bin.5_k119_5513_2	SARG|gb|BAG33043.1|ARO:3003920|pgpB	28.0	143	301	236	4.06e-11	60.8
VatanenT_2016_SRR4408251_bin.5_k119_5513_2	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	28.0	143	301	236	4.06e-11	60.8
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.5	537	631	655	1.52e-111	348
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	4.22e-111	347
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	SARG|gb|AKA86814|ARO:3003746|optrA	36.3	537	631	655	4.22e-111	347
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.5	537	631	655	8.35e-111	346
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	3.26e-110	344
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	3.26e-110	344
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	3.26e-110	344
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	4.58e-110	344
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	4.58e-110	344
VatanenT_2016_SRR4408251_bin.5_k119_7175_2	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.3	537	631	655	6.45e-110	343
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|gb|BAI83385.1|ARO:3003440|mecB	26.5	407	467	674	4.88e-25	107
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	26.7	404	467	674	1.17e-24	106
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|gi|686316946|ref|WP_031873770.1|	25.1	338	467	668	1.55e-24	105
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|gi|1028095782|ref|WP_063852670.1|	24.9	338	467	668	2.07e-24	105
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|gi|1028095795|ref|WP_063852683.1|	24.9	338	467	668	2.07e-24	105
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|gi|1028095789|ref|WP_063852677.1|	24.9	338	467	668	2.07e-24	105
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|gi|282848474|gb|ADB03008.1|	24.6	338	467	668	2.77e-24	105
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	25.7	381	467	665	3.68e-24	104
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|CAA74376	24.9	338	467	668	3.70e-24	104
VatanenT_2016_SRR4408251_bin.5_k119_8167_3	SARG|AAX14397	24.9	338	467	668	3.70e-24	104
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|WP_081853183.1|ARO:3006885|ELM-1	35.1	134	205	313	1.00e-13	67.4
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|AJP77059|ARO:3003670|PEDO-1	31.7	139	205	286	2.13e-13	66.2
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|EU408354.1.gene5.p01	31.7	139	205	294	3.10e-13	65.9
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	38.2	102	205	342	1.02e-12	64.7
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|AYD68552.1|ARO:3005018|LMB-1	30.1	146	205	304	2.95e-12	63.2
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|AB636283.1.gene1.p01	35.0	100	205	280	3.08e-11	60.1
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|WP_041884311.1|ARO:3006972|PLN-1	30.4	138	205	289	8.23e-11	58.9
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|WP_122630825.1|ARO:3006873|EAM-1	29.5	105	205	318	4.31e-10	57.0
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	SARG|gb|WP_122630831.1|ARO:3006864|CRD3-1	26.3	99	205	303	1.02e-09	55.8
VatanenT_2016_SRR4408251_bin.5_k119_10636_23	NCBI|WP_071766402.1|1|1|blaMSI-1|blaMSI-1_fam|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_MSI-1|AMR|beta-lactam	34.1	91	205	289	1.78e-09	55.1
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|AAV80410	27.7	336	609	651	1.53e-28	119
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|AJ514254.gene.p01	44.3	140	609	640	4.63e-28	118
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|L42544.gene.p01	43.0	142	609	651	4.82e-28	118
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|Q02652	42.6	141	609	639	5.90e-25	108
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	megares|MEG_7148|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETM_1	41.8	146	609	644	1.06e-24	107
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|ABB70054	43.0	142	609	639	1.84e-24	107
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|ABI81214	43.0	142	609	639	1.84e-24	107
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|AAK17952	43.0	142	609	639	1.84e-24	107
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|ABN11268	43.0	142	609	639	1.84e-24	107
VatanenT_2016_SRR4408251_bin.5_k119_10988_3	SARG|BAB71968	43.0	142	609	639	1.84e-24	107
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.3	205	291	255	2.29e-27	105
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gb|AAK76137.1|ARO:3000024|patA	27.8	216	291	564	1.10e-19	87.8
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gi|921979807|ref|WP_053271336.1|	27.7	242	291	648	7.19e-19	85.5
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	25.6	238	291	579	1.66e-18	84.3
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.6	238	291	579	5.51e-18	82.8
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	24.3	239	291	578	1.35e-17	81.6
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.4	236	291	664	1.44e-17	81.6
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gb|APB03219.1|ARO:3003986|TaeA	24.5	274	291	648	5.28e-09	55.8
VatanenT_2016_SRR4408251_bin.5_k119_15040_7	SARG|gi|514904648|ref|WP_016630030.1|	23.2	194	291	498	3.58e-06	47.0
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gb|AAV85982.1|ARO:3000535|macB	32.4	272	279	644	2.73e-36	135
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|502669352|ref|WP_012905216.1|	31.6	225	279	648	3.35e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|835330218|ref|WP_047457825.1|	29.9	234	279	648	4.55e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|YP_001453760	29.9	234	279	648	4.55e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|754927849|ref|WP_042284850.1|	30.3	231	279	648	4.55e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|757782629|ref|WP_043001213.1|	30.8	224	279	648	1.54e-25	104
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|Q83LR7	30.9	223	279	648	1.54e-25	104
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|647325472|ref|WP_025760953.1|	30.9	223	279	648	1.54e-25	104
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|647323678|ref|WP_025760497.1|	30.9	223	279	648	1.54e-25	104
VatanenT_2016_SRR4408251_bin.5_k119_15040_8	SARG|gi|763407609|ref|WP_044264203.1|	30.8	224	279	648	1.54e-25	104
VatanenT_2016_SRR4408251_bin.5_k119_15040_9	SARG|gb|APB03216.1|ARO:3003982|LlmA	55.4	287	290	287	5.19e-117	337
VatanenT_2016_SRR4408251_bin.5_k119_17947_17	SARG|ZP_02952732	28.8	139	792	652	2.69e-10	62.8
VatanenT_2016_SRR4408251_bin.5_k119_17947_17	SARG|L20800.gene.p01	28.8	139	792	652	2.69e-10	62.8
VatanenT_2016_SRR4408251_bin.5_k119_17947_17	SARG|ZP_02632674	28.8	139	792	660	2.71e-10	62.8
VatanenT_2016_SRR4408251_bin.5_k119_17947_17	SARG|YP_002850805	28.8	139	792	652	8.08e-10	61.2
VatanenT_2016_SRR4408251_bin.5_k119_17947_17	SARG|NP_348076	28.8	139	792	652	1.40e-09	60.5
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.0	211	258	575	1.96e-16	77.4
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|664042835|ref|WP_030582300.1|	28.7	202	258	604	1.08e-13	69.3
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|913055317|ref|WP_050357634.1|	28.7	202	258	603	1.46e-13	68.9
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|948040364|ref|WP_056699531.1|	28.7	202	258	603	1.46e-13	68.9
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|827013130|ref|WP_047175495.1|	28.7	202	258	603	1.46e-13	68.9
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|695891735|ref|WP_032792824.1|	28.7	202	258	603	1.46e-13	68.9
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|1045390184|ref|WP_065479071.1|	28.1	199	258	605	1.46e-13	68.9
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|517787730|ref|WP_018957938.1|	28.7	202	258	610	1.47e-13	68.9
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|764446018|ref|WP_044369325.1|	28.4	201	258	605	1.97e-13	68.6
VatanenT_2016_SRR4408251_bin.5_k119_17947_25	SARG|gi|662129758|ref|WP_030081404.1|	28.7	202	258	605	1.97e-13	68.6
VatanenT_2016_SRR4408251_bin.5_k119_17947_31	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.0	266	445	346	3.59e-25	104
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	SARG|gi|1004359922|gb|AMP42228.1|	25.8	434	607	639	1.43e-26	113
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	434	607	629	7.67e-26	111
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	ResF|tet(O/W)_4_AM889121_1	26.0	434	607	639	7.93e-26	111
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	434	607	629	1.81e-25	110
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	ResF|tet(O/W)_5_AM889122_1	26.0	434	607	639	1.87e-25	110
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	SARG|ACI02041	26.3	437	607	639	1.87e-25	110
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.6	446	607	629	2.40e-25	109
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	ResF|tet(O/W)_2_AM889119_1	25.6	446	607	639	2.48e-25	109
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	SARG|ABN80187	25.6	434	607	640	2.49e-25	109
VatanenT_2016_SRR4408251_bin.5_k119_17947_40	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.8	434	607	629	4.25e-25	108
VatanenT_2016_SRR4408251_bin.5_k119_18997_5	SARG|gb|AAC75314.1|ARO:3003578|pmrF	27.8	317	321	322	7.56e-35	128
VatanenT_2016_SRR4408251_bin.5_k119_25094_3	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.1	851	934	1024	8.40e-119	386
VatanenT_2016_SRR4408251_bin.5_k119_25094_3	SARG|gb|CAA53189|ARO:3000521|mupA	31.1	851	934	1024	8.40e-119	386
VatanenT_2016_SRR4408251_bin.5_k119_25094_3	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	31.1	851	934	1024	1.17e-118	385
VatanenT_2016_SRR4408251_bin.5_k119_25094_3	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	31.1	851	934	1024	1.17e-118	385
VatanenT_2016_SRR4408251_bin.5_k119_25094_3	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	28.6	887	934	1033	3.31e-103	344
VatanenT_2016_SRR4408251_bin.5_k119_25094_3	SARG|gb|AEY83581|ARO:3000510|mupB	28.6	887	934	1033	3.31e-103	344
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.1	242	347	355	2.13e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	33.1	242	347	355	2.13e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	SARG|ACM47285	33.1	242	347	363	2.39e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.1	248	347	356	2.98e-26	106
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.9	248	347	356	4.10e-26	105
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.3	248	347	356	2.02e-25	103
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.1	248	347	346	2.42e-25	103
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.6	244	347	355	3.78e-25	103
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	SARG|BAE96115	31.6	244	347	355	3.78e-25	103
VatanenT_2016_SRR4408251_bin.5_k119_25120_3	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	31.3	195	347	209	1.64e-21	90.1
VatanenT_2016_SRR4408251_bin.5_k119_25120_11	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.8	219	520	359	9.98e-20	89.7
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.2	229	238	232	2.78e-49	160
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.2	229	238	232	2.78e-49	160
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.8	230	238	231	7.62e-49	159
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.2	227	238	232	8.82e-48	156
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.5	230	238	231	6.82e-47	154
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.0	230	238	231	1.92e-46	153
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	230	238	231	1.92e-46	153
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.1	230	238	231	7.65e-46	151
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.2	230	238	229	1.02e-45	151
VatanenT_2016_SRR4408251_bin.5_k119_25120_12	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.1	230	238	231	2.15e-45	150
VatanenT_2016_SRR4408251_bin.5_k119_25120_17	SARG|gi|446048013|ref|WP_000125868.1|	28.1	221	511	648	9.32e-21	94.7
VatanenT_2016_SRR4408251_bin.5_k119_25120_17	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.6	203	511	664	7.90e-16	79.3
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.4	297	321	323	3.83e-36	131
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|YP_002333394	35.4	297	321	323	5.36e-36	131
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|AF310956.2.gene5.p01	35.4	297	321	323	7.48e-36	130
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|gi|498515089|ref|WP_010815296.1|	35.4	297	321	323	2.84e-35	129
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|gi|985522333|ref|WP_060811962.1|	35.4	297	321	323	2.84e-35	129
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|Q47748	35.4	297	321	323	5.53e-35	128
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	35.4	297	321	323	5.53e-35	128
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|FJ349556.1.gene5.p01	32.8	293	321	326	1.64e-33	124
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|CAB61228	37.1	278	321	322	2.11e-33	124
VatanenT_2016_SRR4408251_bin.5_k119_26079_2	SARG|AAF72362	36.0	275	321	323	2.15e-33	124
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	42.7	150	159	164	1.61e-41	135
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	43.4	166	159	166	3.93e-40	132
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|CAE53424	44.4	144	159	169	1.12e-37	125
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	44.4	162	159	166	1.17e-36	123
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|gb|AAD01868.1|ARO:3002867|dfrF	40.9	159	159	164	2.22e-36	122
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	44.9	136	159	162	3.84e-34	116
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|CAL48457	39.3	163	159	183	9.70e-34	116
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|gb|WP_149100971.1|ARO:3005351|DfrA39	39.2	158	159	165	1.18e-33	115
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	40.6	160	159	164	4.62e-33	114
VatanenT_2016_SRR4408251_bin.5_k119_26127_13	SARG|gb|AAO04716.1|ARO:3002865|dfrC	39.6	144	159	161	6.81e-32	110
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	ResF|nimI_1_FJ940884_1	47.6	164	167	165	1.28e-50	159
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	ResF|nimI_1_FJ940887_1	47.0	164	167	165	1.28e-50	159
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	ResF|nimI_1_FJ940889_1	47.6	164	167	165	1.81e-50	158
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	ResF|nimI_1_FJ940886_1	46.3	164	167	165	1.04e-49	156
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	megares|MEG_4190|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	50.3	153	167	152	1.40e-49	155
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	megares|MEG_4193|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	49.7	153	167	152	1.40e-49	155
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	megares|MEG_4192|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	49.7	153	167	154	4.23e-49	154
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	NCBI|WP_021588763.1|1|1|nimI|nimI|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimI|AMR|nitroimidazole	46.6	163	167	172	5.19e-49	155
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	megares|MEG_4191|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	49.0	153	167	152	1.13e-48	153
VatanenT_2016_SRR4408251_bin.5_k119_26688_27	ResF|nimI_1_FJ940883_1	46.3	164	167	165	1.19e-48	154
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.6	382	573	579	4.07e-37	144
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.8	382	573	579	2.54e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|948137056|ref|WP_056795395.1|	25.9	456	573	602	2.12e-34	136
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|1033217078|gb|OAR27197.1|	25.6	449	573	601	9.40e-34	134
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|817122037|ref|WP_046494699.1|	26.6	455	573	613	1.02e-33	134
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|496018010|ref|WP_008742581.1|	25.4	452	573	623	6.49e-33	132
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|764446018|ref|WP_044369325.1|	25.3	455	573	605	1.05e-32	131
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|AF170880.4.gene1.p01	26.6	451	573	615	1.12e-32	131
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|947982677|ref|WP_056642336.1|	25.1	466	573	626	1.19e-32	131
VatanenT_2016_SRR4408251_bin.5_k119_26688_38	SARG|gi|639892676|ref|WP_024755698.1|	25.1	466	573	631	1.23e-32	131
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.7	378	607	582	1.55e-48	177
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|860594225|ref|WP_048475168.1|	33.7	306	607	620	1.09e-43	164
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|496018010|ref|WP_008742581.1|	33.3	306	607	623	1.13e-43	164
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|493394434|ref|WP_006350564.1|	38.1	244	607	602	1.20e-43	164
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|748767925|ref|WP_040019608.1|	36.6	238	607	623	9.80e-43	161
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|516574297|ref|WP_017949361.1|	33.0	306	607	620	2.39e-42	160
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|655413091|ref|WP_028811890.1|	36.1	244	607	603	3.68e-42	159
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|664317010|ref|WP_030845774.1|	37.0	238	607	605	3.76e-42	159
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|663286402|ref|WP_030292859.1|	37.0	238	607	605	3.76e-42	159
VatanenT_2016_SRR4408251_bin.5_k119_27297_17	SARG|gi|663342223|ref|WP_030341347.1|	37.0	238	607	605	3.76e-42	159
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|496018010|ref|WP_008742581.1|	35.0	234	592	623	3.36e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|1045390184|ref|WP_065479071.1|	34.2	234	592	605	5.31e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	31.2	260	592	574	5.46e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|926376632|ref|WP_053705806.1|	35.5	234	592	620	5.98e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|748767925|ref|WP_040019608.1|	36.3	234	592	623	6.12e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|921231571|ref|WP_053176464.1|	35.5	234	592	620	8.07e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|917172177|ref|WP_051778889.1|	35.5	234	592	620	1.09e-35	140
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|919568551|ref|WP_052871170.1|	35.5	234	592	620	1.09e-35	140
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|799286378|ref|WP_045936958.1|	35.5	234	592	620	1.09e-35	140
VatanenT_2016_SRR4408251_bin.5_k119_27297_18	SARG|gi|917127754|ref|WP_051734466.1|	35.5	234	592	620	1.09e-35	140
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|1045390184|ref|WP_065479071.1|	28.9	484	576	605	2.26e-60	209
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|497748188|ref|WP_010062372.1|	28.7	484	576	605	3.13e-60	209
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|517347347|ref|WP_018522839.1|	29.2	511	576	601	4.04e-60	209
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|664180077|ref|WP_030714054.1|	28.7	484	576	605	8.34e-60	208
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|516795764|ref|WP_018105258.1|	29.0	511	576	601	1.08e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|639148059|ref|WP_024490169.1|	29.4	511	576	602	1.10e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|695842130|ref|WP_032755430.1|	28.6	507	576	603	1.12e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|505420018|ref|WP_015607120.1|	28.6	507	576	603	1.12e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|764446018|ref|WP_044369325.1|	28.5	484	576	605	1.16e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_9	SARG|gi|926400371|ref|WP_053728483.1|	28.2	567	576	603	1.55e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.9	557	594	582	8.14e-63	216
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|516574297|ref|WP_017949361.1|	30.1	525	594	620	1.14e-59	208
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|739906046|ref|WP_037756452.1|	30.1	525	594	620	3.01e-59	207
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|772774655|ref|WP_045322518.1|	29.5	546	594	620	2.11e-58	205
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|648667297|ref|WP_026359044.1|	29.3	526	594	605	8.24e-58	203
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|926376632|ref|WP_053705806.1|	28.9	546	594	620	1.06e-57	203
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|799286378|ref|WP_045936958.1|	28.9	546	594	620	2.81e-57	202
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|917127754|ref|WP_051734466.1|	28.9	546	594	620	2.81e-57	202
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|926294973|ref|WP_053631154.1|	28.9	546	594	620	2.81e-57	202
VatanenT_2016_SRR4408251_bin.5_k119_29155_10	SARG|gi|926356413|ref|WP_053687351.1|	28.9	546	594	620	3.88e-57	201
VatanenT_2016_SRR4408251_bin.5_k119_35092_5	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	31.2	231	326	310	2.70e-29	113
VatanenT_2016_SRR4408251_bin.5_k119_35092_5	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	29.1	254	326	308	6.92e-28	109
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|695840638|ref|WP_032753940.1|	36.3	237	261	646	1.49e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|1016530977|ref|WP_063106245.1|	36.3	237	261	646	1.49e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|556337683|ref|WP_023297316.1|	36.7	237	261	646	1.49e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|852138723|ref|WP_048293411.1|	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|1000904163|ref|WP_061155197.1|	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|765283866|ref|WP_044612790.1|	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|985815823|ref|WP_060876116.1|	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|YP_002239469	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|496081332|ref|WP_008805839.1|	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35092_34	SARG|gi|751264306|ref|WP_040974017.1|	36.3	237	261	646	2.05e-35	132
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.0	887	803	1024	4.58e-32	133
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.0	887	803	1024	4.58e-32	133
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.7	888	803	1033	4.63e-32	133
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	SARG|gb|AEY83581|ARO:3000510|mupB	22.7	888	803	1033	4.63e-32	133
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.3	889	803	1024	6.06e-32	132
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	SARG|gb|CAA53189|ARO:3000521|mupA	22.3	889	803	1024	6.06e-32	132
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.3	886	803	1107	8.35e-20	94.0
VatanenT_2016_SRR4408251_bin.5_k119_35587_6	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.3	886	803	1107	8.35e-20	94.0
VatanenT_2016_SRR4408251_bin.5_k119_36346_2	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	43.3	97	291	138	6.70e-21	85.5
VatanenT_2016_SRR4408251_bin.5_k119_36346_2	CARD|gb|BAA15221.2|ARO:3000263|marA	28.7	94	291	127	1.28e-13	65.5
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|657888313|ref|WP_029592374.1|	43.7	222	239	648	1.19e-55	187
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gb|AAV85982.1|ARO:3000535|macB	43.6	225	239	644	1.57e-55	186
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|803568669|ref|WP_046077412.1|	42.3	222	239	648	6.22e-55	185
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|446110352|ref|WP_000188207.1|	42.3	222	239	648	6.22e-55	185
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|YP_002382193	42.3	222	239	648	6.22e-55	185
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|803575554|ref|WP_046081557.1|	42.3	222	239	648	6.22e-55	185
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|446110351|ref|WP_000188206.1|	42.3	222	239	648	6.22e-55	185
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|639225329|ref|WP_024561799.1|	43.2	222	239	648	8.65e-55	184
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|639218559|ref|WP_024556062.1|	43.2	222	239	648	8.65e-55	184
VatanenT_2016_SRR4408251_bin.5_k119_38043_3	SARG|gi|554685678|ref|WP_023185565.1|	43.2	220	239	648	1.20e-54	184
VatanenT_2016_SRR4408251_bin.5_k119_38043_7	SARG|gi|313638554|gb|EFS03703.1|	33.9	440	462	453	5.12e-87	272
VatanenT_2016_SRR4408251_bin.5_k119_38043_7	SARG|gi|313614636|gb|EFR88215.1|	34.9	430	462	453	4.42e-85	267
VatanenT_2016_SRR4408251_bin.5_k119_38043_7	SARG|HE999704.1.gene1126.p01	33.6	324	462	337	8.22e-60	198
VatanenT_2016_SRR4408251_bin.5_k119_38043_7	SARG|gi|441473784|emb|CCQ23538.1|	33.6	324	462	336	1.69e-58	194
VatanenT_2016_SRR4408251_bin.5_k119_38043_7	SARG|gi|313619623|gb|EFR91268.1|	37.6	218	462	237	1.34e-43	152
VatanenT_2016_SRR4408251_bin.5_k119_38043_8	SARG|L22689.1.gene1.p01	27.8	187	286	257	6.98e-12	63.2
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.4	559	582	575	4.70e-118	360
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gb|AAK76137.1|ARO:3000024|patA	38.4	523	582	564	1.42e-106	330
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|1045390184|ref|WP_065479071.1|	30.3	557	582	605	4.65e-72	241
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|663350985|ref|WP_030349761.1|	30.6	566	582	613	7.68e-72	241
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|505420018|ref|WP_015607120.1|	30.7	557	582	603	1.21e-71	240
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|664042835|ref|WP_030582300.1|	31.1	557	582	604	1.72e-71	239
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|516795764|ref|WP_018105258.1|	30.5	557	582	601	2.25e-71	239
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|664556405|ref|WP_031071225.1|	30.5	557	582	602	2.30e-71	239
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|695842130|ref|WP_032755430.1|	30.7	557	582	603	3.28e-71	239
VatanenT_2016_SRR4408251_bin.5_k119_38043_10	SARG|gi|817122037|ref|WP_046494699.1|	30.6	568	582	613	7.85e-71	238
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gb|AAK76136.1|ARO:3000025|patB	39.0	510	618	588	6.47e-112	346
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.2	536	618	664	2.78e-106	334
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gb|CDO61516.1|ARO:3003949|efrB	42.2	348	618	362	6.02e-88	276
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gi|664180077|ref|WP_030714054.1|	32.4	592	618	605	1.21e-86	281
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gi|497748188|ref|WP_010062372.1|	32.1	592	618	605	2.37e-86	280
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gi|764446018|ref|WP_044369325.1|	32.1	592	618	605	2.37e-86	280
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.4	598	618	579	2.45e-86	279
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gi|695887424|ref|WP_032788534.1|	32.3	592	618	605	6.50e-86	279
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.4	602	618	579	6.73e-86	278
VatanenT_2016_SRR4408251_bin.5_k119_38043_11	SARG|gi|664556405|ref|WP_031071225.1|	31.6	599	618	602	8.46e-86	278
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|505177635|ref|WP_015364737.1|	26.0	431	458	451	1.14e-40	150
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|ZP_04679156	26.2	431	458	451	2.18e-40	149
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|565830932|ref|WP_023914633.1|	26.5	426	458	451	9.93e-38	142
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|686155635|ref|WP_031787393.1|	25.8	426	458	451	1.89e-37	141
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|446573718|ref|WP_000651064.1|	25.8	426	458	451	1.89e-37	141
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|516415429|ref|WP_017804827.1|	26.3	426	458	451	6.79e-37	139
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|686367913|ref|WP_031894914.1|	26.1	426	458	451	9.35e-37	139
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|486285962|ref|WP_001572033.1|	26.1	426	458	451	1.29e-36	139
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|686309068|ref|WP_031870147.1|	26.1	426	458	451	1.29e-36	139
VatanenT_2016_SRR4408251_bin.5_k119_41816_23	SARG|gi|537465183|ref|WP_020976941.1|	25.6	426	458	451	1.77e-36	138
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|gi|1028100561|ref|WP_063856696.1|	33.8	370	399	349	1.77e-54	182
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|gi|752682279|ref|WP_041330231.1|	33.6	369	399	349	6.88e-54	181
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|DQ212986.1.gene8.p01	33.1	362	399	349	1.35e-53	180
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|gi|405945042|pdb|4FU0|A	33.1	362	399	357	1.66e-53	180
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|gi|765411304|ref|WP_044689514.1|	33.1	362	399	349	2.67e-53	179
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|AAF71281	32.9	362	399	349	7.36e-53	178
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|JF802084.2.gene1.p01	33.3	363	399	343	6.75e-52	176
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|AAZ98839	33.4	371	399	343	1.86e-51	174
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|gi|511041762|ref|WP_016295754.1|	32.2	373	399	343	7.19e-51	173
VatanenT_2016_SRR4408251_bin.5_k119_43776_3	SARG|gi|1002798395|gb|AMN85478.1|	32.9	371	399	343	1.98e-50	172
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|545167026|ref|WP_021521592.1|	28.3	244	491	648	8.79e-15	75.9
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|391288090|gb|EIQ46599.1|	27.0	259	491	645	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|YP_309843	27.0	259	491	648	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|693106883|ref|WP_032260279.1|	27.0	259	491	648	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|920465160|ref|WP_052991191.1|	27.0	259	491	648	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|446110305|ref|WP_000188160.1|	27.4	259	491	648	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|446110307|ref|WP_000188162.1|	27.4	259	491	648	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|446110287|ref|WP_000188142.1|	26.6	259	491	648	1.16e-14	75.5
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|692988230|ref|WP_032177097.1|	27.0	259	491	648	1.54e-14	75.1
VatanenT_2016_SRR4408251_bin.5_k119_44161_51	SARG|gi|693137385|ref|WP_032279889.1|	27.0	259	491	648	1.54e-14	75.1
VatanenT_2016_SRR4408251_bin.5_k119_44161_56	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.7	130	399	639	2.62e-16	79.7
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|L42544.gene.p01	27.5	688	698	651	7.58e-80	266
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|NP_348076	26.6	681	698	652	1.08e-79	266
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|AAV80410	27.3	688	698	651	3.97e-79	264
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|YP_002850805	25.9	696	698	652	5.79e-75	253
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|ZP_02952732	25.7	696	698	652	8.03e-74	250
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|ZP_02632674	25.7	696	698	660	9.46e-74	250
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.0	674	698	639	1.18e-73	249
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|L20800.gene.p01	25.7	696	698	652	2.15e-73	249
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|AAO42740	26.7	674	698	639	3.17e-73	248
VatanenT_2016_SRR4408251_bin.5_k119_44161_57	SARG|AY485126.gene.p01	26.1	686	698	639	8.45e-72	244
VatanenT_2016_SRR4408251_bin.5_k119_44161_61	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.1	1219	1233	1162	0.0	1217
VatanenT_2016_SRR4408251_bin.5_k119_44161_61	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	52.1	1227	1233	1186	0.0	1166
VatanenT_2016_SRR4408251_bin.5_k119_44161_61	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	52.1	1227	1233	1186	0.0	1166
VatanenT_2016_SRR4408251_bin.5_k119_44161_65	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	24.3	259	652	1033	7.32e-10	61.2
VatanenT_2016_SRR4408251_bin.5_k119_44161_65	SARG|gb|AEY83581|ARO:3000510|mupB	24.3	259	652	1033	7.32e-10	61.2
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gb|AML99881.1|ARO:3001327|mdtK	31.3	434	458	474	2.60e-62	208
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|505177635|ref|WP_015364737.1|	21.3	380	458	451	4.90e-17	82.0
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|446573718|ref|WP_000651064.1|	19.7	401	458	451	6.57e-16	78.6
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|446573690|ref|WP_000651036.1|	19.7	401	458	451	1.17e-15	77.8
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|686448604|ref|WP_031928572.1|	19.7	401	458	451	1.17e-15	77.8
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|686309068|ref|WP_031870147.1|	19.7	401	458	451	1.56e-15	77.4
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|446573700|ref|WP_000651046.1|	20.0	401	458	451	1.56e-15	77.4
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|537465183|ref|WP_020976941.1|	19.7	401	458	451	2.07e-15	77.0
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|686155635|ref|WP_031787393.1|	19.2	401	458	451	2.07e-15	77.0
VatanenT_2016_SRR4408251_bin.5_k119_45736_9	SARG|gi|686432388|ref|WP_031921070.1|	20.0	401	458	451	2.07e-15	77.0
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|502669352|ref|WP_012905216.1|	53.0	219	249	648	1.36e-70	227
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|803568669|ref|WP_046077412.1|	52.1	219	249	648	2.67e-70	226
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|446110352|ref|WP_000188207.1|	52.1	219	249	648	2.67e-70	226
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|YP_002382193	52.1	219	249	648	2.67e-70	226
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|803575554|ref|WP_046081557.1|	52.1	219	249	648	2.67e-70	226
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|446110351|ref|WP_000188206.1|	52.1	219	249	648	2.67e-70	226
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|740856590|ref|WP_038641842.1|	52.1	219	249	648	2.83e-69	223
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|922960663|ref|WP_053388845.1|	52.1	219	249	648	2.83e-69	223
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|895898290|ref|WP_048999361.1|	49.6	236	249	646	3.82e-69	223
VatanenT_2016_SRR4408251_bin.5_k119_48326_16	SARG|gi|757799695|ref|WP_043016897.1|	52.1	219	249	648	3.96e-69	223
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	43.6	225	244	343	2.59e-57	184
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|AAA26793|ARO:3003748|oleC	40.8	218	244	325	1.08e-51	169
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	40.8	218	244	325	1.08e-51	169
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	38.5	205	244	293	3.86e-40	139
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|AAR96051.1|ARO:3002894|otrC	34.7	225	244	351	4.76e-35	127
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	34.2	225	244	351	3.55e-34	124
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.7	213	244	258	3.52e-21	88.2
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|AAK76136.1|ARO:3000025|patB	23.3	232	244	588	1.51e-13	68.6
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.1	224	244	664	1.28e-12	65.9
VatanenT_2016_SRR4408251_bin.5_k119_54378_8	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.4	177	244	505	1.37e-10	59.7
VatanenT_2016_SRR4408251_bin.5_k119_54378_16	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.5	244	379	364	3.65e-22	95.5
VatanenT_2016_SRR4408251_bin.5_k119_54378_16	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.5	244	379	364	3.65e-22	95.5
VatanenT_2016_SRR4408251_bin.5_k119_54378_16	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	31.8	214	379	364	1.26e-21	94.0
VatanenT_2016_SRR4408251_bin.5_k119_54378_16	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	31.8	214	379	364	1.26e-21	94.0
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	37.8	201	225	231	8.81e-41	138
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	36.8	201	225	233	2.06e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.2	219	225	219	6.90e-37	127
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.8	223	225	223	1.58e-32	116
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.5	203	225	225	1.17e-28	106
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.5	203	225	225	1.17e-28	106
VatanenT_2016_SRR4408251_bin.5_k119_54378_17	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.3	220	225	229	5.66e-26	99.8
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.5	295	524	365	2.75e-36	137
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.6	293	524	370	7.90e-36	136
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	24.3	301	524	386	6.53e-25	105
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	24.3	301	524	386	6.53e-25	105
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.3	226	524	368	1.73e-24	103
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.3	226	524	367	2.31e-24	103
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	228	524	381	2.78e-24	103
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.1	228	524	381	2.78e-24	103
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.8	228	524	381	3.75e-24	103
VatanenT_2016_SRR4408251_bin.5_k119_54523_21	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.8	228	524	381	3.75e-24	103
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.2	224	232	231	2.41e-62	193
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.9	230	232	231	2.41e-62	193
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.4	231	232	232	4.98e-62	192
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.5	230	232	231	6.84e-62	192
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.0	231	232	232	1.41e-61	191
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	45.4	227	232	228	2.51e-61	191
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.5	230	232	231	2.21e-60	188
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.6	230	232	231	1.26e-59	186
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.8	225	232	232	2.60e-59	186
VatanenT_2016_SRR4408251_bin.5_k119_54523_22	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.7	230	232	231	7.16e-59	184
VatanenT_2016_SRR4408251_bin.5_k119_55089_1	ResF|poxtA-Ef_1_WP094899500.1_1	27.4	201	248	538	5.20e-09	55.1
VatanenT_2016_SRR4408251_bin.5_k119_55089_1	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	27.4	201	248	543	5.22e-09	55.1
VatanenT_2016_SRR4408251_bin.5_k119_55089_1	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	27.4	201	248	543	5.22e-09	55.1
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	SARG|gb|ABA71733.1|ARO:3002972|vanTG	33.9	369	385	712	2.79e-60	206
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	32.8	369	385	711	1.74e-54	190
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	32.7	364	385	712	5.90e-52	183
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.5	361	385	700	2.48e-50	178
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	33.2	319	385	366	2.59e-49	169
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	35.6	315	385	700	4.45e-49	175
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	34.6	315	385	700	1.91e-46	167
VatanenT_2016_SRR4408251_bin.5_k119_55725_7	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	34.3	315	385	706	9.80e-46	166
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	CARD|gb|ABD30512.1|ARO:3000839|arlS	30.6	245	334	451	2.35e-33	127
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	27.0	263	334	392	2.07e-23	98.6
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	CARD|gb|AAD51347.1|ARO:3003067|smeS	32.0	206	334	467	1.07e-21	94.4
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.1	203	334	381	2.07e-19	87.0
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.1	203	334	381	2.07e-19	87.0
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.3	212	334	381	5.20e-19	85.9
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.3	212	334	381	5.20e-19	85.9
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.8	213	334	381	9.59e-19	85.1
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.8	213	334	381	9.59e-19	85.1
VatanenT_2016_SRR4408251_bin.5_k119_55725_13	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.9	228	334	370	4.63e-17	80.1
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.9	224	225	228	2.60e-45	149
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.8	224	225	219	1.27e-43	145
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.1	229	225	231	6.24e-41	138
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.1	229	225	231	6.24e-41	138
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	230	225	231	1.95e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.8	230	225	232	3.98e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.8	230	225	232	3.98e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	34.1	226	225	231	6.70e-37	128
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	32.5	234	225	252	6.30e-36	126
VatanenT_2016_SRR4408251_bin.5_k119_55725_14	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.6	138	225	204	1.17e-06	46.6
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.4	363	604	582	1.08e-48	177
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.0	272	604	575	1.93e-38	148
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|664352659|ref|WP_030880307.1|	31.7	290	604	601	5.81e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|662754041|ref|WP_030125200.1|	31.7	290	604	601	7.85e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|664100597|ref|WP_030638327.1|	31.7	290	604	601	7.85e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|505389066|ref|WP_015576168.1|	31.7	290	604	601	7.85e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|503923650|ref|WP_014157644.1|	31.7	290	604	601	7.85e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|695865802|ref|WP_032778631.1|	31.4	290	604	605	6.60e-35	138
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|1045390184|ref|WP_065479071.1|	31.4	290	604	605	1.62e-34	137
VatanenT_2016_SRR4408251_bin.5_k119_55725_17	SARG|gi|497748188|ref|WP_010062372.1|	32.1	293	604	605	2.94e-34	136
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.0	317	596	575	1.11e-37	146
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|1045390184|ref|WP_065479071.1|	35.3	238	596	605	4.96e-37	144
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|695865802|ref|WP_032778631.1|	34.9	238	596	605	1.66e-36	143
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|662754041|ref|WP_030125200.1|	34.5	238	596	601	3.96e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|664100597|ref|WP_030638327.1|	34.5	238	596	601	3.96e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|505389066|ref|WP_015576168.1|	34.5	238	596	601	3.96e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|503923650|ref|WP_014157644.1|	34.5	238	596	601	3.96e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|664352659|ref|WP_030880307.1|	34.5	238	596	601	5.36e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|497748188|ref|WP_010062372.1|	35.2	236	596	605	5.54e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_18	SARG|gi|764446018|ref|WP_044369325.1|	34.5	238	596	605	5.54e-36	141
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|505177635|ref|WP_015364737.1|	28.5	438	482	451	2.02e-44	160
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|ZP_04679156	29.3	440	482	451	7.22e-43	156
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|488374619|ref|WP_002444004.1|	26.5	438	482	452	2.69e-42	155
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|686155635|ref|WP_031787393.1|	27.7	440	482	451	3.87e-37	140
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|446573718|ref|WP_000651064.1|	27.7	440	482	451	3.87e-37	140
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|446573715|ref|WP_000651061.1|	27.1	439	482	451	7.31e-37	140
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|1006223553|ref|WP_061745579.1|	26.1	414	482	451	1.38e-36	139
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|686396521|ref|WP_031908504.1|	26.9	439	482	451	1.90e-36	139
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|446573692|ref|WP_000651038.1|	26.9	439	482	451	1.90e-36	139
VatanenT_2016_SRR4408251_bin.5_k119_55725_20	SARG|gi|565830932|ref|WP_023914633.1|	26.9	439	482	451	2.61e-36	138
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|AUI09862.1	35.1	279	268	287	5.14e-47	157
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|gi|486033774|ref|WP_001505252.1|	30.6	265	268	271	1.07e-32	119
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|AJ459418.gene.p01	30.2	265	268	263	1.25e-32	119
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	30.6	265	268	271	2.10e-32	119
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|DQ464881.1.gene2.p01	30.6	265	268	271	2.95e-32	118
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|gi|638947703|ref|WP_024439711.1|	30.6	265	268	271	2.95e-32	118
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|gi|970263436|ref|WP_058647620.1|	30.2	265	268	263	3.45e-32	118
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|gi|550552396|ref|WP_022631488.1|	30.6	265	268	271	5.78e-32	117
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|gi|490067892|ref|WP_003970071.1|	30.2	265	268	271	8.09e-32	117
VatanenT_2016_SRR4408251_bin.5_k119_56614_3	SARG|gi|487670925|ref|WP_001756235.1|	30.2	265	268	271	8.09e-32	117
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|gi|507044560|ref|WP_016115614.1|	27.6	221	289	306	1.91e-21	90.9
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|gi|500448961|gb|EOP61695.1|	29.4	211	289	306	1.80e-20	88.2
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|gi|500465078|gb|EOP76697.1|	29.4	211	289	306	1.80e-20	88.2
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|YP_001373621	28.1	221	289	318	2.10e-20	88.2
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|gi|447195835|ref|WP_001273091.1|	30.8	201	289	306	4.35e-19	84.3
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|ZP_04081918	28.0	211	289	306	8.21e-19	83.6
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	SARG|gi|447195836|ref|WP_001273092.1|	30.3	201	289	306	1.13e-18	83.2
VatanenT_2016_SRR4408251_bin.5_k119_57575_1	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	28.6	206	289	550	6.54e-08	52.4
VatanenT_2016_SRR4408251_bin.5_k119_58698_11	SARG|M58472.1.gene1.p01	40.7	59	193	209	4.38e-07	47.4
VatanenT_2016_SRR4408251_bin.5_k119_58698_11	SARG|gb|APB03220.1|ARO:3003987|VatI	35.5	93	193	210	1.52e-06	45.8
VatanenT_2016_SRR4408251_bin.5_k119_58698_16	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	34.5	84	205	159	7.83e-07	46.2
VatanenT_2016_SRR4408251_bin.5_k119_58698_16	NCBI|CAJ68095.1|1|1|vanZ1|vanZ1|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ1|AMR|glycopeptide	50.0	44	205	169	3.10e-06	44.7
VatanenT_2016_SRR4408251_bin.5_k119_58698_18	NCBI|WP_087347987.1|1|1|rphC|rphC||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphC|AMR|rifamycin	33.0	94	544	868	8.01e-09	57.4
VatanenT_2016_SRR4408251_bin.5_k119_61063_6	CARD|gb|TKW44661.1|ARO:3005040|YajC	33.8	74	142	112	6.04e-10	52.4
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|AJ514254.gene.p01	24.0	667	684	640	1.54e-42	162
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|ABI81214	23.5	660	684	639	4.41e-37	146
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|YP_002738300	23.3	660	684	639	1.44e-36	144
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|BAB71968	23.5	660	684	639	2.60e-36	144
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|ABB70054	23.3	660	684	639	3.49e-36	143
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|X04388.gene.p01	23.2	660	684	639	6.28e-36	142
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|gi|319894056|gb|ADV76307.1|	23.0	660	684	639	3.66e-35	140
VatanenT_2016_SRR4408251_bin.5_k119_62368_1	SARG|AM180355.1.gene636.p01	23.2	660	684	639	9.33e-33	133
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.6	219	227	219	1.29e-52	168
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.5	228	227	232	1.92e-40	137
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.5	228	227	232	1.92e-40	137
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	36.4	228	227	231	2.07e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	228	227	231	2.07e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.6	228	227	231	4.57e-38	131
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.5	228	227	231	4.57e-38	131
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.1	228	227	231	1.81e-37	129
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	34.2	237	227	252	2.19e-37	130
VatanenT_2016_SRR4408251_bin.5_k119_62368_11	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.9	225	227	231	5.57e-36	125
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	26.7	206	432	388	1.78e-15	76.6
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.7	206	432	388	1.78e-15	76.6
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.6	203	432	386	1.01e-14	74.3
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	25.6	203	432	386	1.01e-14	74.3
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	26.2	206	432	386	1.35e-14	73.9
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.2	206	432	386	1.35e-14	73.9
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	26.1	203	432	384	1.78e-14	73.6
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	26.1	203	432	384	1.78e-14	73.6
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.6	203	432	382	4.22e-14	72.4
VatanenT_2016_SRR4408251_bin.5_k119_62368_12	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	25.6	203	432	382	4.22e-14	72.4
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	221	219	8.67e-49	158
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	221	219	1.23e-48	157
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	221	220	1.26e-48	157
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.3	221	221	220	1.78e-48	157
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.6	215	221	219	2.49e-45	149
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.9	223	221	228	4.53e-42	141
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	SARG|ZP_02848503	37.5	216	221	221	1.05e-41	140
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	36.4	220	221	223	1.39e-39	134
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.9	234	221	232	9.86e-39	132
VatanenT_2016_SRR4408251_bin.5_k119_63054_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.7	219	221	223	1.10e-38	132
VatanenT_2016_SRR4408251_bin.5_k119_63054_44	SARG|gb|AAC75089.1|ARO:3003577|ugd	60.2	412	413	388	3.99e-170	480
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gb|AAV85982.1|ARO:3000535|macB	30.8	416	416	644	2.66e-43	159
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|487394343|ref|WP_001665309.1|	30.6	421	416	648	3.15e-41	153
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|485888314|ref|WP_001481465.1|	30.9	421	416	648	4.31e-41	153
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|486424500|ref|WP_001614292.1|	30.9	421	416	648	4.31e-41	153
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|487410704|ref|WP_001678420.1|	30.9	421	416	648	5.90e-41	152
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|446110286|ref|WP_000188141.1|	30.9	421	416	648	5.90e-41	152
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|919893883|ref|WP_052903625.1|	30.4	421	416	648	1.11e-40	152
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|928831144|ref|WP_053888514.1|	30.4	421	416	648	1.51e-40	151
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|391266580|gb|EIQ25529.1|	30.6	421	416	648	2.07e-40	151
VatanenT_2016_SRR4408251_bin.5_k119_63587_2	SARG|gi|1016529760|ref|WP_063105172.1|	30.9	421	416	648	2.07e-40	151
VatanenT_2016_SRR4408251_bin.5_k119_63587_40	ResF|penA_1_AF515059_1	24.7	592	738	581	2.85e-40	155
VatanenT_2016_SRR4408251_bin.5_k119_63587_45	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	33.9	434	421	444	1.15e-64	213
VatanenT_2016_SRR4408251_bin.5_k119_63852_28	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	29.0	694	659	703	1.74e-82	273
VatanenT_2016_SRR4408251_bin.5_k119_69904_8	SARG|gi|1035706844|ref|WP_064548272.1|	32.6	89	942	648	1.42e-07	54.3
VatanenT_2016_SRR4408251_bin.5_k119_70115_2	SARG|gb|APB03220.1|ARO:3003987|VatI	47.1	51	222	210	8.72e-07	47.0
VatanenT_2016_SRR4408251_bin.5_k119_70115_7	SARG|AAN28721	46.5	86	304	108	1.99e-18	78.2
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	39.0	223	234	255	5.88e-50	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|446110305|ref|WP_000188160.1|	40.8	233	234	648	1.86e-47	164
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|Q83LR7	40.3	233	234	648	6.85e-47	163
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|647325472|ref|WP_025760953.1|	40.3	233	234	648	6.85e-47	163
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|647323678|ref|WP_025760497.1|	40.3	233	234	648	6.85e-47	163
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|446110301|ref|WP_000188156.1|	40.3	233	234	648	9.48e-47	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|446110272|ref|WP_000188127.1|	40.8	233	234	648	1.31e-46	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|922960663|ref|WP_053388845.1|	39.4	236	234	648	1.31e-46	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|757799695|ref|WP_043016897.1|	39.4	236	234	648	1.82e-46	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_14	SARG|gi|491270241|ref|WP_005128370.1|	41.4	220	234	648	1.82e-46	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.4	574	573	575	3.12e-109	337
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gb|AAK76137.1|ARO:3000024|patA	31.6	564	573	564	9.92e-82	265
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gb|AAC74000.1|ARO:3003950|msbA	25.9	536	573	582	1.12e-52	188
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	33.6	375	573	574	3.57e-52	186
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.2	426	573	579	4.91e-46	169
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.0	493	573	664	3.48e-45	168
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.1	427	573	579	1.15e-44	166
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	SARG|gi|921979807|ref|WP_053271336.1|	31.3	211	573	648	6.60e-18	86.3
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	26.2	206	573	487	2.40e-07	52.4
VatanenT_2016_SRR4408251_bin.5_k119_70245_15	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	26.2	206	573	487	5.53e-07	51.2
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gb|AAK76136.1|ARO:3000025|patB	33.5	579	582	588	1.19e-100	316
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.1	498	582	664	3.29e-94	301
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.9	330	582	362	1.44e-86	272
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.1	528	582	582	2.29e-84	273
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gi|517347347|ref|WP_018522839.1|	29.6	571	582	601	6.51e-79	259
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gi|496018010|ref|WP_008742581.1|	29.9	552	582	623	7.66e-79	259
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gi|516795764|ref|WP_018105258.1|	29.6	571	582	601	4.86e-78	257
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gi|860594225|ref|WP_048475168.1|	29.7	553	582	620	1.04e-77	256
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gi|926376632|ref|WP_053705806.1|	29.2	551	582	620	1.08e-76	254
VatanenT_2016_SRR4408251_bin.5_k119_70245_16	SARG|gi|928900436|ref|WP_053931243.1|	29.8	547	582	600	1.89e-76	253
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.1	227	227	232	5.35e-52	167
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.1	227	227	232	5.35e-52	167
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.0	228	227	229	1.39e-51	166
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.9	227	227	231	2.94e-51	165
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	234	227	231	2.94e-51	165
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	227	227	231	4.16e-51	164
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.9	219	227	228	5.38e-51	164
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.8	230	227	231	1.18e-50	163
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	227	227	231	2.35e-50	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_27	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.0	230	227	231	2.35e-50	162
VatanenT_2016_SRR4408251_bin.5_k119_70245_28	CARD|gb|CYF42523.1|ARO:3004047|kdpD	27.4	266	331	885	5.35e-18	84.0
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.3	225	227	255	5.43e-60	188
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|851928815|ref|WP_048221086.1|	46.4	222	227	648	5.30e-59	195
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|780033092|ref|WP_045444768.1|	46.4	222	227	648	5.30e-59	195
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|751264306|ref|WP_040974017.1|	46.8	222	227	646	2.72e-58	193
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|985815823|ref|WP_060876116.1|	46.4	222	227	646	5.28e-58	192
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|YP_002239469	46.4	222	227	646	5.28e-58	192
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|695840638|ref|WP_032753940.1|	46.4	222	227	646	5.28e-58	192
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|556492128|ref|WP_023339842.1|	46.4	222	227	646	5.28e-58	192
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|gi|498115003|ref|WP_010429159.1|	46.4	220	227	646	7.36e-58	192
VatanenT_2016_SRR4408251_bin.5_k119_70245_29	SARG|Q83LR7	46.8	222	227	648	7.57e-58	192
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	SARG|X63451.gene.p01	26.8	261	377	550	1.91e-15	76.6
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	26.8	261	377	550	1.91e-15	76.6
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	SARG|M80346.gene.p01	27.5	251	377	551	1.91e-15	76.6
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	27.5	251	377	551	1.91e-15	76.6
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.2	223	377	550	1.44e-12	67.8
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	33.3	99	377	461	6.14e-07	50.1
VatanenT_2016_SRR4408251_bin.5_k119_70245_34	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	31.0	84	377	461	4.42e-06	47.4
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|507079934|ref|WP_016150692.1|	32.9	283	309	660	2.34e-38	142
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|507083067|ref|WP_016153816.1|	32.5	283	309	660	1.54e-37	140
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|765458296|ref|WP_044714032.1|	32.5	283	309	660	1.54e-37	140
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|696375142|ref|WP_032949690.1|	32.2	283	309	660	2.89e-37	139
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|507086291|ref|WP_016157032.1|	32.5	283	309	660	3.96e-37	139
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|1002399350|ref|WP_061382108.1|	32.9	283	309	660	3.96e-37	139
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|489117806|ref|WP_003027650.1|	32.2	283	309	660	5.41e-37	138
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|851965596|ref|WP_048234849.1|	32.9	283	309	660	7.41e-37	138
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|851981245|ref|WP_048240645.1|	31.9	282	309	660	7.41e-37	138
VatanenT_2016_SRR4408251_bin.5_k119_70245_50	SARG|gi|851899656|ref|WP_048211088.1|	30.9	317	309	660	1.01e-36	137
VatanenT_2016_SRR4408251_bin.5_k119_70245_53	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	36.4	332	343	349	2.91e-58	191
VatanenT_2016_SRR4408251_bin.5_k119_70245_53	SARG|AJ249217.gene.p01	36.4	332	343	349	8.12e-58	189
VatanenT_2016_SRR4408251_bin.5_k119_70245_53	SARG|AXY65402.1	36.9	336	343	357	5.47e-53	177
VatanenT_2016_SRR4408251_bin.5_k119_70245_53	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	34.5	325	343	349	1.45e-50	171
VatanenT_2016_SRR4408251_bin.5_k119_70245_53	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	34.5	325	343	349	1.45e-50	171
VatanenT_2016_SRR4408251_bin.5_k119_70245_53	SARG|gb|AIX48090.1|ARO:3004599|clcD	33.8	325	343	349	5.63e-50	169
VatanenT_2016_SRR4408251_bin.5_k119_70245_55	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.4	573	658	718	1.51e-95	308
VatanenT_2016_SRR4408251_bin.5_k119_70245_63	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.1	275	395	346	6.43e-28	111
